CTOs on the Move

CaptureRx

www.capturerx.com

 
Founded in 2000, San Antonio-based CaptureRx is a healthcare technology company and leading 340B solution provider that puts people first, touching millions of patient lives through customer obsession and innovative products and services that support relationships among payers, providers, pharmacies and patients. Our solutions manage inventory and financial flow for 340B prescriptions filled at contract pharmacies and perform the eligibility checks required to comply with 340B program requirements. Using a process that`s seamless to the covered entity, pharmacy and patient, our Cumulus platform has processed more than 190 million patient encounters and more than 750 million switch claims. Currently, CaptureRx ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.capturerx.com
  • 219 East Houston Street Suite 200
    San Antonio, TX USA 78205
  • Phone: 888.345.6424

Executives

Name Title Contact Details

Similar Companies

Service Drug Company

Service Drug Company is a Delta, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amgenix International

Amgenix International is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mountain Rose Herbs

Mountain Rose Herbs is a Sedro Woolley, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioniche Pharma

Bioniche Pharma is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radius Health

Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.